Richtlijn HIV
Deze pagina is het laatst bewerkt op 28 apr 2021 om 12:32. | Deze pagina is 35.811 maal bekeken.

Lijst met verwijzingen naar andere richtlijnen

Uit Richtlijnen HIV

(Verschil tussen bewerkingen)
Ga naar: navigatie, zoeken
(41 tussenliggende versies worden niet weergegeven)
Regel 1: Regel 1:
-
In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd:  
+
In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:<br>
-
<br>
+
{| width="100%" border="1" align="left" cellspacing="1" cellpadding="1"
-
 
+
|-
-
{| width="100%" cellspacing="0" cellpadding="0" border="1" style="mso-yfti-irow:0;mso-yfti-firstrow:yes" class="MsoTableGrid"
+
| valign="top" align="left" | '''Pagina'''<br>
 +
| width="45" valign="top" align="left" | '''Link naar andere richtlijn'''
 +
|-
 +
| valign="top" align="left" | [[Inhoud|'''Inhoud''']]
 +
| width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn
 +
|-
 +
| valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>'''
 +
| width="45" valign="top" align="left" | <br>
 +
|-
 +
| valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br>
 +
| width="45" valign="top" align="left" | Aidsinfo NIH
|-
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassenen met hiv|2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv]]<br>  
-
'''Pagina'''
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border:solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
| valign="top" align="left" | [[2.3. Tijdelijk onderbreken van antiretrovirale therapie|2.3. Tijdelijk onderbreken van anti-retrovirale therapie]]<br>  
-
'''Verwijzing naar andere richtlijnen'''
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
 
+
|-
-
|- style="mso-yfti-irow:1"
+
| valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv|2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv]]<br>  
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
'''&lt;a'''
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen|Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen]]'''  
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Richtlijn%20HIV"&gt;Hoofdpagina''' '''(=inhoudsopgave)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
| width="45" valign="top" align="left" | Aidsinfo NIH<br>Kinderformularium
-
 
+
|-
-
<br>
+
| valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
<span style="mso-bidi-font-weight:bold">
+
| valign="top" align="left" | [[4.2. Spiegelbepaling]]<br>  
-
</span>
+
| width="45" valign="top" align="left" | Aidsinfo NIH<br>TDM-protocollen
-
 
+
|-
-
|- style="mso-yfti-irow:2"
+
| valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br>  
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie|Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie]]<br>'''  
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
<span style="mso-bidi-font-weight:bold">
+
|-
-
</span>
+
| valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | Aidsinfo NIH Perinatal<br> Landelijk hiv expositie protocol neonaten
-
|- style="mso-yfti-irow:3"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>'''  
-
'''&lt;a'''
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
 
+
|-
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%201.%20Achtergrondinformatie%20bij%20de%20ontwikkeling%20en%20herziening%20van%20deze%20richtlijn%20en%20inleiding"&gt;Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn''' '''en inleiding&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
| valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]'''  
-
 
+
| width="45" valign="top" align="left" |  
-
<br>
+
|-
-
 
+
| valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde]]
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | EACS
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
|-
-
 
+
| valign="top" align="left" | [[9.6. Doseringen bij gestoorde leverfunctie]]
-
|- style="mso-yfti-irow:4"
+
| width="45" valign="top" align="left" | EACS
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
&lt;a
+
| valign="top" align="left" | [[9.7. Doseringen bij gestoorde nierfunctie]]
-
 
+
| width="45" valign="top" align="left" | EACS
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Procedure%20herziening"&gt;Procedure herziening&lt;/a&gt;
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1|Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1]]<br>'''  
-
<br>
+
| width="45" valign="top" align="left" | <br>
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[10.1. Hepatitis B]]<br>  
-
NVHB Richtlijn 2007
+
| width="45" valign="top" align="left" | Aidsinfo NIH<br>EACS
-
 
+
|-
-
|- style="mso-yfti-irow:5"
+
| valign="top" align="left" | [[10.2. Hepatitis C|10.2. Hepatitis C]]
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | HCV richtsnoer
-
&lt;a
+
|-
-
 
+
| valign="top" align="left" | [[10.3. HCC surveillance|10.3. HCC surveillance]]
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Samenstelling%20kernwerkgroep"&gt;Samenstelling kernwerkgroep&lt;/a&gt;
+
| width="45" valign="top" align="left" | HBV richtsnoer
-
 
+
|-
-
<br>
+
| valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie|Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | KNCV
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
<br>
+
| valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | EACS<br>
-
|- style="mso-yfti-irow:6"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | '''[[Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten|Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten]] <br>'''  
-
&lt;a
+
| width="45" valign="top" align="left" | Aidsinfo NIH
-
 
+
|-
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Overzicht%20belangen%20werkgroepleden"&gt;Overzicht belangen werkgroepleden&lt;/a&gt;
+
| valign="top" align="left" | [[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie|'''Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie''']]
-
 
+
| width="45" valign="top" align="left" | Aidsinfo NIH<br>Nationale Antibioticaboekje<br>SWAB richtlijnen
-
<br>
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiereductie (PEP)|Hoofdstuk 16. Transmissiemanagement]]<br>'''  
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | <br>
-
|- style="mso-yfti-irow:7"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[16.1. Prikaccidenten]]<br>  
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Definities"&gt;Definities&lt;/a&gt;
+
| width="45" valign="top" align="left" | LCI
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[16.2. Seksaccidenten]]<br>  
-
<br>
+
| width="45" valign="top" align="left" | LCI/RIVM
-
 
+
|-
-
|- style="mso-yfti-irow:8"
+
| valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>'''  
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | <br>
-
Geschiedenis per pagina van deze richtlijn (= huidige pagina)
+
|-
-
 
+
| valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br>  
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | RIVM<br>NHG
-
|- style="mso-yfti-irow:9"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br>  
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
| width="45" valign="top" align="left" | RIVM
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [https://richtlijnhiv.nvhb.nl/index.php/Addendum:%C2%A0SOA-richtlijn '''Addendum:''' SOA-richtlijn]
-
|- style="mso-yfti-irow:10"
+
| width="45" valign="top" align="left" | SOA richtlijn
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
'''&lt;a'''
+
| valign="top" align="left" | [http://richtlijnhiv.nvhb.nl/images/2/22/PrEP-richtlijn-Nederland-8-september-2016-met-logos.pdf '''Addendum:'''&nbsp;Pre-exposure profylaxe (PrEP) richtlijn]
-
 
+
| width="45" valign="top" align="left" | PrEP-richtlijn
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%202.%20Therapie%20bij%20volwassenen"&gt;Hoofdstuk''' '''2. Therapie bij volwassenen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:11"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.1.%20Wanneer%20beginnen?"&gt;2.1. Wanneer beginnen?&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:12"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20wanneer%20starten"&gt;Onderbouwing wanneer starten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:13"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.1"&gt;Literatuur 2.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:14"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.2.%20Keuze%20van%20antiretrovirale%20therapie%20bij%20na%C3%AFeve%20volwassen%20pati%C3%ABnten"&gt;2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH  
+
-
 
+
-
|- style="mso-yfti-irow:15"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.2"&gt;Literatuur 2.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:16"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.3.%20Tijdelijk%20onderbreken%20van%20HAART"&gt;2.3. Tijdelijk onderbreken van HAART&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH  
+
-
 
+
-
|- style="mso-yfti-irow:17"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/T%C2%BD%20van%20antiretrovirale%20middelen"&gt;T½ van antiretrovirale middelen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:18"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.4.%20Richtlijn%20anti-retrovirale%20therapie%20bij%20voorbehandelde%20pati%C3%ABnten"&gt;2.4. Richtlijn <span class="SpellE">anti-retrovirale</span> therapie bij <span class="SpellE">voorbehandelde</span> patiënten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH  
+
-
 
+
-
|- style="mso-yfti-irow:19"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:20"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%203.%20Behandeling%20van%20HIV-1%20infectie%20bij%20kinderen"&gt;Hoofdstuk''' '''3. Behandeling van HIV-1 infectie bij kinderen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:21"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:22"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%204.%20Monitoring"&gt;Hoofdstuk''' '''4. Monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:23"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.1.%20Controles%20HIV-pati%C3%ABnten%20%28polikliniek%29"&gt;4.1. Controles HIV-patiënten (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:24"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20eerste%20consult%20bij%20HIV-seropositieve%20pati%C3%ABnt%20%28polikliniek%29"&gt;Bij eerste consult bij <span class="SpellE">HIV-seropositieve</span> patiënt (polikliniek)&lt;/a&gt;&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20instellen%20op%20antiretrovirale%20therapie%20%28polikliniek%29" _fcknotitle=true _fcksavedurl="Bij instellen op antiretrovirale therapie (polikliniek)"&gt;Bij instellen op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:25"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Eerste%20controle%20na%20instellen%20op%20anti-retrovirale%20therapie%204-6%20weken%20na%20start%20%28polikliniek%29"&gt;Eerste controle na instellen op <span class="SpellE">anti-retrovirale</span> therapie 4-6 weken na start (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:26"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20op%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:27"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20zonder%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten zonder antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:28"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.2.%20Spiegelbepaling"&gt;4.2. Spiegelbepaling&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:29"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.3.%20Resistentiebepalingen"&gt;4.3. Resistentiebepalingen&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:30"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:31"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%205.%20Diagnostiek%20en%20behandeling%20primaire%20HIV-infectie"&gt;Hoofdstuk''' '''5. Diagnostiek en behandeling primaire <span class="SpellE">HIV-infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:32"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:33"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%206.%20Therapietrouw%20bevorderende%20maatregelen"&gt;Hoofdstuk''' '''6. Therapietrouw bevorderende maatregelen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:34"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.1.%20Therapietrouw%20be%C3%AFnvloedende%20factoren"&gt;6.1. Therapietrouw beïnvloedende factoren&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:35"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.1"&gt;Literatuur 6.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:36"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.2.%20Therapietrouw%20bevorderende%20interventies"&gt;6.2. Therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:37"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20therapietrouw%20bevorderende%20interventies"&gt;Onderbouwing therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:38"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.2"&gt;Literatuur 6.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:39"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:40"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%207.%20Preventie%20van%20moeder-kind%20overdracht:%20zwangerschap,%20bevalling%20en%20neonatale%20periode"&gt;Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale''' '''periode&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH Perinatal</span>
+
-
 
+
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
-
 
+
-
|- style="mso-yfti-irow:41"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%207"&gt;Literatuur 7&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:42"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:43"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%208.%20HIV-2%20bij%20volwassenen:%20Behandeling%20en%20monitoring"&gt;Hoofdstuk''' '''8. HIV-2 bij volwassenen: Behandeling en monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH</span>
+
-
 
+
-
|- style="mso-yfti-irow:44"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%208"&gt;Literatuur 8&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:45"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:46"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%209.%20Bijzondere%20omstandigheden"&gt;Hoofdstuk''' '''9. Bijzondere omstandigheden&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:47"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.1.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20na%20braken"&gt;9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:48"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.2.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20bij%20vergeten%20van%20slikmoment"&gt;9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:49"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.3.%20Marge%20tussen%20twee%20innames"&gt;9.3. Marge tussen twee innames&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:50"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.4.%20Inname%20medicatie%20bij%20overschrijden%20tijdzones"&gt;9.4. Inname medicatie bij overschrijden tijdzones&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:51"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.5.%20Adviezen%20m.b.t.%20gebruik%20anti-HIV%20middelen%20door%20de%20sonde"&gt;9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:52"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.6.%20Doseringen%20bij%20gestoorde%20lever-%20en%20nierfunctie"&gt;9.6. Doseringen bij gestoorde lever- en nierfunctie&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:53"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:54"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2010.%20Behandeling%20van%20hepatitis%20B/C-virus%20co%C3%AFnfectie%20bij%20HIV-1%20positieve%20pati%C3%ABnten"&gt;Hoofdstuk 10. Behandeling van hepatitis B/C-virus <span class="SpellE">coïnfectie</span>''' '''bij HIV-1 positieve patiënten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:55"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.1.%20Hepatitis%20B"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.1. Hepatitis B</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
EACS  
+
-
 
+
-
|- style="mso-yfti-irow:56"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.2.%20Hepatitis%20C%C2%A0%28acuut%29"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.2. Hepatitis C&nbsp;(<span class="SpellE">acuut</span>)</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language: EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
NL aanbevelingen
+
-
 
+
-
NEAT
+
-
 
+
-
|- style="mso-yfti-irow:57"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Levels%20of%20evidence"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">Levels of evidence</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:58"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2010.2"&gt;Literatuur 10.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:59"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.3.%20Hepatitis%20C%C2%A0%28chronisch%29"&gt;10.3. Hepatitis C&nbsp;(chronisch)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
EACS
+
-
 
+
-
|- style="mso-yfti-irow:60"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:61"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2011.%20Behandeling%20van%20tuberculose%20bij%20pati%C3%ABnten%20met%20een%20HIV-infectie"&gt;Hoofdstuk''' '''11. Behandeling van tuberculose bij patiënten met een HIV-<span class="SpellE">infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:62"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2011"&gt;Literatuur 11&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:63"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:64"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2012.%20Comorbiditeit%20en%20bijwerkingen"&gt;Hoofdstuk''' '''12. Comorbiditeit en bijwerkingen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span style="mso-bidi-font-weight:bold">EACS</span>  
+
-
 
+
-
|- style="mso-yfti-irow:65"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:66"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2013.%20Screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Hoofdstuk''' '''13. Screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:67"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:68"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2013"&gt;Literatuur 13&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:69"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:70"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2014.%20Interacties"&gt;Hoofdstuk''' '''14. Interacties&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:71"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:72"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2015.%20Profylaxe%20en%20behandeling%20van%20opportunistische%20infectie"&gt;Hoofdstuk''' '''15. Profylaxe en behandeling van opportunistische infectie&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:73"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:74"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig <span class="SpellE">sexueel</span> contact
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:75"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2016.%20Transmissiereductie%20%28PEP%29"&gt;Hoofdstuk''' '''16. <span class="GramE">Transmissiereductie</span> (PEP)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:76"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.1.%20Prikaccidenten"&gt;16.1. Prikaccidenten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCI  
+
-
 
+
-
|- style="mso-yfti-irow:77"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.2.%20Seksaccidenten"&gt;16.2. Seksaccidenten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCI/RIVM  
+
-
 
+
-
|- style="mso-yfti-irow:78"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:79"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2017.%20Vaccinatiebeleid"&gt;Hoofdstuk''' '''17. Vaccinatiebeleid&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:80"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.1.%20Vaccinaties%20bij%20HIV-ge%C3%AFnfecteerde%20kinderen"&gt;17.1. Vaccinaties bij <span class="SpellE">HIV-geïnfecteerde</span> kinderen&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:81"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.2.%20Vaccinatie%20tegen%20influenza"&gt;17.2. Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
NHG Standaard
+
-
 
+
-
|- style="mso-yfti-irow:82"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20influenza"&gt;Onderbouwing Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:83"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.2"&gt;Literatuur 17.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:84"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.3.%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29"&gt;17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:85"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29%20%28Pneumokokken%29"&gt;Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:86"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.3"&gt;Literatuur 17.3&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:87"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.4.%20Vaccinaties%20tegen%20Hepatitis%20A%20en%20B"&gt;17.4. Vaccinaties tegen Hepatitis A en B&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:88"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.5.%20Vaccinatie%20bij%20HIV-ge%C3%AFnfecteerde%20reizigers"&gt;17.5. Vaccinatie bij <span class="SpellE">HIV-geïnfecteerde</span><span class="SpellE">reizigers</span>&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCR
+
-
 
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:89"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bureau%27s%20voor%20reizigersadvisering"&gt;<span class="SpellE">Bureau's</span> voor reizigersadvisering&lt;/a&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:90"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:91;mso-yfti-lastrow:yes"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2018.%20Kostenoverzicht%20antiretrovirale%20middelen"&gt;Hoofdstuk''' '''18. Kostenoverzicht antiretrovirale middelen&lt;/a&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|}
|}
-
 
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt; &lt;/div&gt; &lt;/body&gt;&lt;/html&gt;
 

Versie op 23 feb 2021 10:12

In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:

Pagina
Link naar andere richtlijn
Inhoud SOA richtlijn
PrEP richtlijn
Hoofdstuk 2. Therapie bij volwassenen

2.1. Wanneer beginnen?
Aidsinfo NIH
2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv
Aidsinfo NIH
2.3. Tijdelijk onderbreken van anti-retrovirale therapie
Aidsinfo NIH
2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv
Aidsinfo NIH
Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen Aidsinfo NIH
Kinderformularium
Hoofdstuk 4. Monitoring
Aidsinfo NIH
4.2. Spiegelbepaling
Aidsinfo NIH
TDM-protocollen
4.3. Resistentiebepalingen
Aidsinfo NIH
Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie
Aidsinfo NIH
Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode
Aidsinfo NIH Perinatal
Landelijk hiv expositie protocol neonaten
Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring
Aidsinfo NIH
Hoofdstuk 9. Bijzondere omstandigheden
9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde EACS
9.6. Doseringen bij gestoorde leverfunctie EACS
9.7. Doseringen bij gestoorde nierfunctie EACS
Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1

10.1. Hepatitis B
Aidsinfo NIH
EACS
10.2. Hepatitis C HCV richtsnoer
10.3. HCC surveillance HBV richtsnoer
Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie
KNCV
Hoofdstuk 12. Comorbiditeit en bijwerkingen
EACS
Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten
Aidsinfo NIH
Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie Aidsinfo NIH
Nationale Antibioticaboekje
SWAB richtlijnen
Hoofdstuk 16. Transmissiemanagement

16.1. Prikaccidenten
LCI
16.2. Seksaccidenten
LCI/RIVM
Hoofdstuk 17. Vaccinatiebeleid

17.2. Vaccinatie tegen influenza
RIVM
NHG
17.4. Vaccinaties tegen Hepatitis A en B
RIVM
Addendum: SOA-richtlijn SOA richtlijn
Addendum: Pre-exposure profylaxe (PrEP) richtlijn PrEP-richtlijn